Option chain shows key data for CENTRAL & EASTERN EUROPE's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CENTRAL & EASTERN EUROPE.

CENTRAL & EASTERN EUROPE (NYSE:CEE) Stock, Option Chain

CENTRAL & EASTERN EUROPE

CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.

Mining,Cart,In,Silver,,Gold,,Copper,Mine

Commodities

Management

GOLD

TSX:CEE

Endeavour appointed Ian Cockerill, the Deputy Chairman, as the new CEO, effective immediately.

Endeavour Fires CEO For Misconduct And Irregularities Linked To Asset Sale

News

Intraday Update

Markets

Movers

Trading Ideas

AACG

AAOI

ABCB

ABMD

ACCO

ACEL

ACGL

ACHC

ACHV

ACIU

ACRE

ACRX

ACST

ACTG

ADES

ADMP

ADMS

ADNT

ADOM

ADPT

ADTN

AEHR

AEIS

AERI

AEZS

AFGC

AFIN

AFMD

AGFS

AGLE

AGRO

AGYS

AIMC

AIMT

AINV

AIRT

AKCA

AKTS

AKTX

ALBO

ALDX

ALEX

ALGN

ALGT

Stocks That Hit 52-Week Lows On Monday

ALTR

ANDE

ANGI

ANGO

ANIP

AOSL

APLE

APWC

ARCC

ARKR

ARLP

ASIX

ASTC

ATNI

ATRO

AVGO

AWSM

AXDX

BBBY

BLUE

BNED

BNFT

DECK

DENN

DISCB

DLTR

DXPE

EDAP

EGBN

EGRX

EMMA

EOLS

EPAY

ESCA

ESXB

ETTX

EXFO

EXLS

FGEN

FNKO

FORR

FPRX

FRBK

FRSX

JBLU

JCTCF

JRSH

KALV

LYFT

MACK

MESA

MGLN

MGTA

MIDD

MORF

MOTS

MRCC

MRIN

NTWK

NUVA

NVEE

NVTA

ORTX

OSIS

OSTK

OSUR

Stocks That Hit 52-Week Lows On Friday

The Central and Eastern Europe Fund, Inc. (The) Common Stock

CENTRAL & EASTERN EUROPE FUND, INC.

Ceres Inc

CEEK VR

UpSnap Inc

The Central and Eastern Europe Fund, Inc. (NYSE:<a href="https://www.benzinga.com/stock/CEE#NYSE">CEE</a>) (the "Fund"). As previously reported, certain of the Fund's Russian holdings have been valued at zero since March 14, 2022 in light of measures adopted by the Russian Central Bank and Government, as well as sanctions implemented by the United States and other countries in response to Russia's invasion of Ukraine. The effects of the sanctions and measures adopted by the Russian Central Bank and Government are far-reaching and include, among others, the freezing of certain Russian assets held by entities, such as the Fund, that are organized in countries viewed as "unfriendly" by the Russian Government.
The Fund's investment manager has been monitoring the situation closely and, as previously disclosed, has observed occasional privately negotiated transactions in depositary receipts of certain non-sanctioned Russian issuers taking place (at prices that are generally deeply discounted from those taking place through the facilities of the Moscow Stock Exchange). On May 30, 2024, the Fund announced that in May 2024 the Fund had been successful in selling depositary receipts of one non-sanctioned Russian issuer in such a privately negotiated transaction resulting in positive impact to the Fund's net asset value ("NAV"). In August and to date in September 2024, the Fund was successful in selling additional depositary receipts of five non-sanctioned Russian issuers in privately negotiated transactions resulting in positive impact to the Fund's NAV.
The Fund will continue to monitor developments in this area and may make further opportunistic sales of depositary receipts for Russian securities to the extent that such sales are deemed to be in the best interests of the Fund and its stockholders and consistent with applicable sanctions and other laws and regulations. However, there can be no assurances that any further such sales will be feasible or considered to be in the best interests of the Fund. The Fund notes that pursuant to a license issued by the Office of Foreign Asset Control of the US Department of Treasury ("OFAC"), transactions in certain Russian equities are currently permitted through October 12, 2024. Any future transactions by the Fund in Russian equities and in depositary receipts for such equities after such date will be prohibited unless a license permitting such a transaction is obtained from OFAC. There can be no assurance that such licenses, if requested, will be granted. Also, it should be noted that nine of the Fund's remaining twelve positions in Russian securities are held as either "local shares," or depositary receipts for securities of issuers that are subject to U.S. sanctions such that it would not be possible for the Fund to sell them, absent receipt of special permissions granted by the U.S., which permissions are unlikely to be forthcoming if requested at the present time. Moreover, a recent Russian Presidential Decree may result in the expropriation of certain Russian assets held by certain foreign investors, which potentially could include the Fund.

Government

Regulations

Asset Sales

Central and Eastern Europe Fund Sells Russian Assets, Boosts NAV Amid Sanctions

<h3>Companies Reporting Before The Bell</h3>
&bull; Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
&bull; InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is projected to report quarterly loss at $0.20 per share on revenue of $1.42 million.
&bull; Fennec Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.67 million.
&bull; Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $218.97 million.
&bull; VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) is expected to report quarterly loss at $0.03 per share on revenue of $8.95 million.
&bull; Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) is expected to report quarterly earnings at $2.29 per share on revenue of $1.79 billion.
&bull; Exscientia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAI#NASDAQ">EXAI</a>) is expected to report quarterly loss at $0.35 per share on revenue of $17.05 million.
&bull; Direxion Daily CSI China Internet Index Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#NYSE">CWEB</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $32.93 million.
&bull; Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is likely to report quarterly earnings at $0.88 per share on revenue of $720.40 million.
&bull; Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) is projected to report quarterly earnings at $0.73 per share on revenue of $1.80 billion.
&bull; Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is projected to report quarterly earnings at $1.02 per share on revenue of $724.20 million.
&bull; Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) is expected to report quarterly loss at $0.47 per share on revenue of $747.35 million.
&bull; Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $382.28 million.
&bull; LiqTech Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) is likely to report quarterly loss at $0.24 per share on revenue of $5.40 million.
&bull; MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $5.32 million.
&bull; Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) is projected to report earnings for its fourth quarter.
&bull; Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is estimated to report earnings for its Fiscal Year 2023.
&bull; Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) is estimated to report earnings for its fourth quarter.
&bull; FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) is likely to report quarterly earnings at $3.88 per share on revenue of $546.75 million.
&bull; Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) is expected to report quarterly earnings at $2.64 per share on revenue of $3.03 billion.
&bull; Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) is likely to report quarterly earnings at $2.66 per share on revenue of $15.83 billion.
&bull; X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) is expected to report earnings for its fourth quarter.
&bull; Lufax Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LU#NYSE">LU</a>) is likely to report quarterly loss at $0.02 per share on revenue of $1.05 billion.
&bull; Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $22.20 million.
&bull; Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) is projected to report quarterly loss at $0.51 per share on revenue of $8.20 million.
&bull; Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) is likely to report earnings for its fourth quarter.
&bull; Kirkland&#39;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) is expected to report quarterly earnings at $0.42 per share on revenue of $167.22 million.
&bull; Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $27.69 million.
&bull; MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is likely to report earnings for its fourth quarter.
&bull; Nano Dimension (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNDM#NASDAQ">NNDM</a>) is likely to report earnings for its fourth quarter.
&bull; Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) is likely to report quarterly earnings at $0.59 per share on revenue of $280.27 million.
&bull; Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $138.29 million.
&bull; CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) is estimated to report quarterly loss at $0.34 per share on revenue of $30.88 million.
&bull; Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) is estimated to report quarterly loss at $0.18 per share on revenue of $14.85 million.
&bull; SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is likely to report earnings for its fourth quarter.
&bull; 111 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YI#NASDAQ">YI</a>) is likely to report earnings for its fourth quarter.
&bull; Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) is projected to report quarterly loss at $0.07 per share on revenue of $22.63 million.
&bull; CENTRAL &amp; EASTERN EUROPE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEE#NYSE">CEE</a>) is expected to report earnings for its Fiscal Year 2023.
<h3>Companies Reporting After The Bell</h3>
&bull; Largo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGO#NASDAQ">LGO</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $47.10 million.
&bull; Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) is projected to report quarterly loss at $1.92 per share on revenue of $17.05 million.
&bull; Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is projected to report quarterly earnings at $5.00 per share on revenue of $3.19 billion.
&bull; Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) is estimated to report quarterly loss at $0.99 per share on revenue of $49.15 million.
&bull; Vitru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRU#NASDAQ">VTRU</a>) is projected to report earnings for its fourth quarter.
&bull; Scholastic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) is projected to report quarterly loss at $0.80 per share on revenue of $329.21 million.
&bull; Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $700.50 million.
&bull; Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $15.06 million.
&bull; Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) is likely to report quarterly loss at $0.08 per share on revenue of $5.30 million.
&bull; Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $13.55 million.
&bull; Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) is projected to report quarterly loss at $2.55 per share on revenue of $13.55 million.
&bull; HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $8.60 million.
&bull; Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is likely to report quarterly earnings at $0.74 per share on revenue of $12.28 billion.
&bull; FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) is likely to report quarterly earnings at $3.53 per share on revenue of $22.05 billion.
&bull; Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $5.31 million.
&bull; Abacus Life (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is estimated to report earnings for its fourth quarter.
&bull; AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $567.63 million.
&bull; Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) is expected to report quarterly loss at $0.11 per share on revenue of $2.70 million.
&bull; CaliberCos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) is likely to report quarterly loss at $0.17 per share on revenue of $4.25 million.
&bull; Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) is estimated to report quarterly loss at $0.18 per share on revenue of $3.71 million.
&bull; Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) is estimated to report quarterly loss at $1.43 per share on revenue of $380 thousand.
&bull; Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $65.95 million.
&bull; TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) is expected to report quarterly loss at $0.43 per share on revenue of $16.39 million.
&bull; One Stop Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>) is projected to report quarterly loss at $0.04 per share on revenue of $13.01 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

Earnings

ALUR

AMPX

APYX

ASXC

BIOL

BZUN

CBUS

CCLD

CREX

CUTR

CWEB

DERM

DRCT

DXLG

EXAI

FENC

GAMB

HYPR

IFRX

INKT

IPHA

KIRK

LIQT

LULU

LUNR

MDWD

MLYS

NNDM

RMTI

SCHL

SCVL

SNDL

TELA

TITN

VRME

VTRU

WELL

XFOR

Earnings Scheduled For March 21, 2024

Endeavour Mining (LSE: EDV) announced the abrupt termination of CEO Sébastien de Montessus, citing "serious misconduct" and irregularities linked to the <a href="https://www.benzinga.com/news/asset-sales">sale of a company asset</a>. 
Following the news, shares dropped by 14% before erasing some losses during the Friday session.
Endeavour is a constituent of the FTSE 100 Index while also listed on the Toronto Stock Exchange.
According to a <a href="https://www.endeavourmining.com/media/news/endeavour-announces-ceo-termination">statement</a>, the London-based company took decisive action after uncovering an alleged &#8220;irregular payment instruction&#8221; amounting to $5.9 million related to an asset sale. 
Additionally, an external investigation into de Montessus&#8217;s conduct with colleagues, prompted by allegations from October, led to his dismissal.
See Also: <a href="https://www.benzinga.com/markets/commodities/24/01/36452207/4-mining-stocks-to-watch-in-2024-aura-oceanagold-alphamin-b2gold">4 Mining Stocks To Watch In 2024: Aura, OceanaGold, Alphamin, B2Gold</a>
Per <a href="https://www.ft.com/content/ede4ad77-4118-4055-954c-649be23313a7">the</a> Financial Times, De Montessus expressed dissatisfaction with the swift termination, citing how he was given only a 48-hour notice and no proper opportunity to address the raised concerns.
He acknowledged instructing an unnamed creditor in 2021 to offset a debt owed to Endeavour for essential security equipment to protect its partners and employees in an unspecified conflict zone. 
Despite claiming that the decision had no additional cost to the company and did not personally benefit him, de Montessus admitted failing to inform the board of this arrangement, labeling it a &#8220;lapse in judgment.&#8221;
Endeavour appointed Ian Cockerill, the Deputy Chairman, as the new CEO, effective immediately. Cockerill has over four decades of experience in the global resources industry. Previously, he served as CEO of Gold Fields Ltd (JSE: GFI). And Anglo Coal, a subsidiary of Anglo American plc.
During his seven-year tenure as a CEO, de Montessus executed transformative strategies through deals and mine-building, replacing small and high-cost operations with flagship projects. 
He was active with acquisitions, buying Teranga Gold Corp and Semafo Inc, but also backed away from acquiring Centamin Plc (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CEE#TSX">CEE</a>) and Acacia Mining Plc, which eventually was sold to Barrick Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>). Yet, share prices have been volatile over those seven years, marking an unremarkable 30% growth.
In 2023, the stock lost 13%, with the largest shareholder, Egyptian billionaire Naguib Sawiris, selling over 3.7 million shares. Over the last five years, he reduced his stake from 30% to 18%.
Now Read: <a href="https://www.benzinga.com/markets/commodities/24/01/36491015/as-spot-uranium-climbs-to-new-highs-cameco-struggles-to-regain-its-footing">As Spot Uranium Climbs To New Highs, Cameco Struggles To Regain Its Footing</a>
Image: Shutterstock

WIIM

AIHS

ARES

BBDO

BSBR

COIN

GWGH

HOOD

ITUB

LPRO

MKTX

MUFG

UPST

Shares of banks and financial services companies are trading lower amid overall market weakness as stocks pull back. Investors continue to weigh the potential impacts of future Fed rate hikes on the sector.

Comments

CENTRAL & EASTERN EUROPE

CENTRAL & EASTERN EUROPE (CEE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga